Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment Strategies.

Abstract

T-cell lymphoma, a form of non-Hodgkin lymphoma, presents significant treatment challenges due to its diverse subtypes and aggressive progression. Jasmine Zain, MD, drawing on her expertise in chimeric antigen receptors (CAR) T-cell therapies, is focused on expanding therapeutic options for T-cell lymphomas, particularly peripheral T-cell lymphoma (PTCL). A critical aspect of treatment development involves recognizing that the subtypes of nodal PTCL are defined by specific genetic pathways, which determine their response to different therapies. This insight has led to the development of more personalized, subtype-specific treatment strategies. Current treatment approaches for PTCL typically involve combinations of chemotherapy, targeted therapies, immunotherapy, and stem cell transplantation. The standard first-line therapy, CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone), has relatively low response rates, highlighting the need for more effective alternatives. While stem cell transplantation is beneficial for certain PTCL subtypes, overall outcomes remain inconsistent. Some targeted therapies have shown efficacy in specific subtypes, but many forms of PTCL are still resistant to available treatments, underscoring the need for further research. In cases of relapsed/refractory disease, stem cell transplantation remains the primary treatment option, though it is associated with significant risks and often impacts patients' quality of life. There is a pressing need for new, less toxic therapies. Several targeted drugs are currently in clinical trials, with the goal of improving treatment options for patients with relapsed/refractory PTCL. Ongoing research into the genetic and molecular characteristics of PTCL aims to develop more individualized therapies that are better suited to each patient's specific disease profile, offering hope for improved outcomes in this challenging lymphoma subtype.